Yield10 Bioscience, Inc. YTEN
We take great care to ensure that the data presented and summarized in this overview for YIELD10 BIOSCIENCE, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in YTEN
Top Purchases
Top Sells
About YTEN
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
Insider Transactions at YTEN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 15
2024
|
Kristi Snell VP Research and CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-11.14%
|
$877
$1.5 P/Share
|
|
Aug 15
2024
|
Oliver P Peoples President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,463
-10.38%
|
$1,463
$1.5 P/Share
|
|
Aug 15
2024
|
Charles B Haaser VP Finance and CAO |
SELL
Payment of exercise price or tax liability
|
Direct |
731
-10.94%
|
$731
$1.5 P/Share
|
|
Aug 15
2024
|
Lynne H Brum VP Planning and Communications |
SELL
Payment of exercise price or tax liability
|
Direct |
731
-11.08%
|
$731
$1.5 P/Share
|
|
Mar 28
2024
|
Robert L Van Nostrand Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,924
+19.69%
|
-
|
|
Mar 28
2024
|
Richard William Hamilton Director |
BUY
Grant, award, or other acquisition
|
Direct |
41,118
+36.16%
|
-
|
|
Mar 28
2024
|
Anthony J Sinskey Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,561
+24.24%
|
-
|
|
Feb 15
2024
|
Kristi Snell VP Research and CSO |
BUY
Grant, award, or other acquisition
|
Direct |
120,000
+48.19%
|
$0
$0.3 P/Share
|
|
Feb 15
2024
|
Lynne H Brum VP Planning and Communications |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+48.0%
|
$0
$0.3 P/Share
|
|
Feb 15
2024
|
Oliver P Peoples President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+45.63%
|
$0
$0.3 P/Share
|
|
Feb 15
2024
|
Charles B Haaser VP Finance and CAO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+47.55%
|
$0
$0.3 P/Share
|
|
Dec 29
2023
|
Robert L Van Nostrand Director |
BUY
Grant, award, or other acquisition
|
Direct |
18,879
+33.96%
|
-
|
|
Dec 29
2023
|
Richard William Hamilton Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,275
+34.08%
|
-
|
|
Dec 29
2023
|
Anthony J Sinskey Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,275
+27.13%
|
-
|
|
Dec 20
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
36,000
-36.08%
|
$0
$0.2 P/Share
|
|
Dec 19
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
36,000
-2.25%
|
$0
$0.21 P/Share
|
|
Dec 08
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
35,000
-2.14%
|
$0
$0.24 P/Share
|
|
Oct 06
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
37,931
-4.16%
|
$0
$0.3 P/Share
|
|
Oct 05
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
10,670
-1.16%
|
$0
$0.3 P/Share
|
|
Oct 04
2023
|
Jack W Schuler |
SELL
Open market or private sale
|
Indirect |
41,399
-4.3%
|
$0
$0.31 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 645K shares |
|---|
| Open market or private sale | 107K shares |
|---|---|
| Payment of exercise price or tax liability | 3.8K shares |